ELI LILLY AND COMPANY (LLY) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.81% | Share-based compensation / revenue. Period ending 2026-06-30. $649.00M ÷ $79.67B × 100 ≈ 0.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 79.67B USD | |
| Stock-based compensation | 649.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $79.67B | $649.00M | (m) | (m) | (m) | 0.81% | (m) | (m) |
| 2026-03-31 | (m) | $72.25B | $633.00M | (m) | (m) | (m) | 0.88% | (m) | (m) |
| 2025-12-31 | (m) | $65.18B | $626.00M | (m) | (m) | (m) | 0.96% | (m) | (m) |
| 2025-09-30 | (m) | $59.42B | $631.80M | (m) | (m) | (m) | 1.06% | (m) | (m) |
| 2025-06-30 | (m) | $53.26B | $613.90M | (m) | (m) | (m) | 1.15% | (m) | (m) |
| 2025-03-31 | (m) | $49.00B | $639.90M | (m) | (m) | (m) | 1.31% | (m) | (m) |
| 2024-12-31 | (m) | $45.04B | $645.60M | (m) | (m) | (m) | 1.43% | (m) | (m) |
| 2024-09-30 | (m) | $40.86B | $623.90M | (m) | (m) | (m) | 1.53% | (m) | (m) |
| 2024-06-30 | (m) | $38.92B | $706.30M | (m) | (m) | (m) | 1.81% | (m) | (m) |
| 2024-03-31 | (m) | $35.93B | $656.70M | (m) | $562.70M | (m) | 1.83% | (m) | Reported |
| 2023-12-31 | (m) | $34.12B | $628.50M | (m) | $485.90M | (m) | 1.84% | (m) | Reported |
| 2023-09-30 | (m) | $32.07B | $601.20M | (m) | $431.70M | (m) | 1.87% | (m) | Reported |
| 2023-06-30 | $8.14B | $29.52B | $470.70M | (m) | $388.60M | 27.58% | 1.59% | (m) | Reported |
| 2023-03-31 | $7.57B | $27.69B | $401.30M | (m) | $349.50M | 27.32% | 1.45% | (m) | Reported |
| 2022-12-31 | $7.19B | $28.54B | $371.10M | (m) | $331.60M | 25.19% | 1.30% | (m) | Reported |
| 2022-09-30 | $7.19B | $29.24B | $353.50M | (m) | $329.00M | 24.58% | 1.21% | (m) | Reported |
| 2022-06-30 | $7.09B | $29.07B | $358.50M | (m) | $331.20M | 24.39% | 1.23% | (m) | Reported |
| 2022-03-31 | $6.96B | $29.32B | $358.30M | (m) | $336.90M | 23.75% | 1.22% | (m) | Reported |
| 2021-12-31 | $7.03B | $28.32B | $342.80M | (m) | $339.80M | 24.81% | 1.21% | (m) | Reported |
| 2021-09-30 | $6.90B | $27.76B | $355.30M | (m) | $347.60M | 24.87% | 1.28% | (m) | Reported |
| 2021-06-30 | $6.66B | $26.73B | $336.90M | (m) | $353.50M | 24.92% | 1.26% | (m) | Reported |
| 2021-03-31 | $6.38B | $25.49B | $321.80M | (m) | $354.90M | 25.03% | 1.26% | (m) | Reported |
| 2020-12-31 | $6.09B | $24.54B | $308.10M | (m) | $359.60M | 24.80% | 1.26% | (m) | Reported |
| 2020-09-30 | $5.83B | $23.21B | $301.90M | (m) | $366.30M | 25.11% | 1.30% | (m) | Reported |
| 2020-06-30 | $5.74B | $22.95B | $305.70M | (m) | $384.00M | 25.03% | 1.33% | (m) | Reported |
| 2020-03-31 | $5.76B | $23.09B | $308.40M | (m) | $406.60M | 24.93% | 1.34% | (m) | Reported |
| 2019-12-31 | $5.59B | $22.32B | $312.40M | (m) | $400.60M | 25.07% | 1.40% | (m) | Reported |
| 2019-09-30 | $5.41B | $21.84B | $303.60M | (m) | $361.90M | 24.75% | 1.39% | (m) | Reported |
| 2019-06-30 | $5.56B | $24.74B | $296.60M | (m) | $345.00M | 22.48% | 1.20% | (m) | Reported |
| 2019-03-31 | $5.43B | $24.68B | $287.30M | (m) | $297.40M | 22.00% | 1.16% | (m) | Reported |
| 2018-12-31 | $5.31B | $24.56B | $279.50M | (m) | $272.10M | 21.61% | 1.14% | (m) | Reported |
| 2018-09-30 | $5.26B | $24.28B | $278.90M | (m) | $256.80M | 21.69% | 1.15% | (m) | Reported |
| 2018-06-30 | $5.26B | $23.87B | $280.30M | (m) | $249.30M | 22.04% | 1.17% | (m) | Reported |
| 2018-03-31 | $5.20B | $23.34B | $280.00M | (m) | $239.60M | 22.28% | 1.20% | (m) | Reported |
| 2017-12-31 | $5.28B | $22.87B | $281.30M | (m) | $225.00M | 23.09% | 1.23% | (m) | Reported |
| 2017-09-30 | $5.26B | $22.47B | $275.90M | (m) | $213.50M | 23.40% | 1.23% | (m) | Reported |
| 2017-06-30 | $5.18B | $22.00B | $267.50M | (m) | $198.80M | 23.52% | 1.22% | (m) | Reported |
| 2017-03-31 | $5.26B | $21.59B | $262.60M | (m) | $188.40M | 24.37% | 1.22% | (m) | Reported |
| 2016-12-31 | $5.24B | $21.22B | $255.30M | (m) | $185.20M | 24.71% | 1.20% | (m) | Reported |
| 2016-09-30 | $5.24B | $20.84B | $246.90M | (m) | $178.00M | 25.14% | 1.18% | (m) | Reported |
| 2016-06-30 | $5.14B | $20.61B | $240.10M | (m) | $170.10M | 24.97% | 1.17% | (m) | Reported |
| 2016-03-31 | $4.98B | $20.18B | $230.90M | (m) | $163.70M | 24.67% | 1.14% | (m) | Reported |
| 2015-12-31 | $4.80B | $19.96B | $217.80M | (m) | $161.20M | 24.03% | 1.09% | (m) | Reported |
| 2015-09-30 | $4.54B | $19.70B | $200.00M | (m) | $154.40M | 23.03% | 1.02% | (m) | Reported |
| 2015-06-30 | $4.64B | $19.62B | $183.80M | (m) | $153.20M | 23.64% | 0.94% | (m) | Reported |
| 2015-03-31 | $4.66B | $19.58B | $166.60M | (m) | $151.90M | 23.82% | 0.85% | (m) | Reported |
| 2014-12-31 | $4.73B | $19.62B | $156.00M | (m) | $148.80M | 24.13% | 0.80% | (m) | Reported |
| 2014-09-30 | $5.02B | $20.30B | $155.20M | (m) | $151.10M | 24.74% | 0.76% | (m) | Reported |
| 2014-06-30 | $5.16B | $21.20B | $153.00M | (m) | $152.80M | 24.33% | 0.72% | (m) | Reported |
| 2014-03-31 | $5.29B | $22.19B | $148.00M | (m) | $157.60M | 23.85% | 0.67% | (m) | Reported |
| 2013-12-31 | $5.53B | $23.11B | $144.90M | (m) | $160.10M | 23.93% | 0.63% | (m) | Reported |
| 2013-09-30 | $5.52B | $23.26B | $146.30M | (m) | $162.90M | 23.73% | 0.63% | (m) | Reported |
| 2013-06-30 | $5.48B | $22.93B | $144.50M | (m) | $170.10M | 23.92% | 0.63% | (m) | Reported |
| 2013-03-31 | $5.47B | $22.60B | $145.80M | (m) | $172.80M | 24.22% | 0.65% | (m) | Reported |
| 2012-12-31 | $5.28B | $22.60B | $141.50M | (m) | $177.80M | 23.35% | 0.63% | (m) | Reported |
| 2012-09-30 | $5.17B | $22.69B | $137.00M | (m) | $185.40M | 22.78% | 0.60% | (m) | Reported |
| 2012-06-30 | $5.11B | $23.40B | $139.00M | (m) | $183.40M | 21.83% | 0.59% | (m) | Reported |
| 2012-03-31 | $5.05B | $24.05B | $137.70M | (m) | $185.50M | 20.99% | 0.57% | (m) | Reported |
| 2011-12-31 | $5.02B | $24.29B | $147.40M | (m) | $186.00M | 20.67% | 0.61% | (m) | Reported |
| 2011-09-30 | $5.10B | $24.43B | $166.50M | (m) | $-191.90M | 20.89% | 0.68% | (m) | Reported |
| 2011-06-30 | $5.04B | $23.93B | $177.00M | (m) | $-189.70M | 21.07% | 0.74% | (m) | Reported |
| 2011-03-31 | $4.97B | $23.43B | $195.20M | (m) | $-187.30M | 21.21% | 0.83% | (m) | Reported |
| 2010-12-31 | $4.88B | $23.08B | $231.00M | (m) | $-185.50M | 21.17% | 1.00% | (m) | Reported |
| 2010-09-30 | $4.66B | $22.82B | $-457.70M | (m) | (m) | 20.43% | -2.01% | (m) | (m) |
| 2010-06-30 | $4.57B | $22.73B | $-336.30M | (m) | (m) | 20.08% | -1.48% | (m) | (m) |
| 2010-03-31 | $4.42B | $22.27B | $-376.10M | (m) | (m) | 19.84% | -1.69% | (m) | (m) |
| 2009-12-31 | $4.33B | $21.84B | $-368.50M | (m) | (m) | 19.81% | -1.69% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $3.84B | $20.37B | $-255.30M | (m) | (m) | 18.85% | -1.25% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $3.49B | $18.63B | $-282.00M | (m) | (m) | 18.71% | -1.51% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |